Connectyx Technologies Holdings Group, Inc. announced it is in licensing discussions for a novel monoclonal antibody (mAB) to treat brain cancer. The company plans to grow its product pipeline through an active program of acquisition, in-licensing and sub-licensing of new technologies. Connectyx has evaluated hundreds of available pharmaceutical assets, and the management, along with the Scientific Advisory Board, have identified a novel mAB available for license to treat pediatric glioblastoma. Pediatric glioblastoma (also sometimes called grade IV astrocytoma) is a malignant brain tumor that is aggressive and without a defined standard therapy. The current prognosis for children with glioblastoma is very poor, with estimates placing the overall median survival rate at 15 months. Connectyx is currently involved in licensing discussions with the owner of the intellectual property for an exclusive worldwide license. This product leverages the Company’s Scientific Advisory Board, that has deep experience in clinical development and manufacturing in this field.